Mucin-Type O-Glycosylation Proximal to β-Secretase Cleavage Site Affects APP Processing and Aggregation Fate

YashoNandini Singh1, Deepika Regmi1, David Ormaza1, Ramya Ayyalasomayajula1, Nancy Vela1, Gustavo Mundim1, Deguo Du1, Dmitriy Minond2 and Maré Cudic1*

1Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, Boca Raton, FL, United States, 2College of Pharmacy and Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, FL, United States

The amyloid-β precursor protein (APP) undergoes proteolysis by β- and γ-secretases to form amyloid-β peptides (Aβ), which is a hallmark of Alzheimer’s disease (AD). Recent findings suggest a possible role of O-glycosylation on APP’s proteolytic processing and subsequent fate for AD-related pathology. We have previously reported that Tyr681-O-glycosylation and the Swedish mutation accelerate cleavage of APP model glycopeptides by β-secretase (amyloidogenic pathway) more than α-secretase (non-amyloidogenic pathway). Therefore, to further our studies, we have synthesized additional native and Swedish-mutated (glyco)peptides with O-GalNAc moiety on Thr663 and/or Ser667 to explore the role of glycosylation on conformation, secretase activity, and aggregation kinetics of Aβ40. Our results show that conformation is strongly dependent on external conditions such as buffer ions and solvent polarity as well as internal modifications of (glyco)peptides such as length, O-glycosylation, and Swedish mutation. Furthermore, the level of β-secretase activity significantly increases for the glycopeptides containing the Swedish mutation compared to their nonglycosylated and native counterparts. Lastly, the glycopeptides impact the kinetics of Aβ40 aggregation by significantly increasing the lag phase and delaying aggregation onset, however, this effect is less pronounced for its Swedish-mutated counterparts. In conclusion, our results confirm that the Swedish mutation and/or O-glycosylation can render APP model glycopeptides more susceptible to cleavage by β-secretase. In addition, this study sheds new light on the possible role of glycosylation and/or glycan density on the rate of Aβ40 aggregation.

Keywords: Alzheimer’s disease, circular dichroism, proteolysis, aggregation kinetics, APP O-glycopeptides

INTRODUCTION

Alzheimer disease (AD) is one of the most common neurodegenerative disorders linked to aging (van Cauwenbergh et al., 2016; Alzheimer’s Association, 2020). It has a profound effect on the economy, health-care system, and the society, and is projected to increase even further as the population ages (Hurd et al., 2013). Genetic, biochemical, and behavioral research suggest that physiologic generation of the Aβ-forming fibrils stems from the proteolytic processing of the amyloid precursor protein (APP), a type 1 transmembrane glycoprotein, by β-secretase (BACE-1) (Hardy and Higgins, 1992; O’Brien and Wong, 2011; Selkoe and Hardy, 2016). This pathway co-exists with the
nonamyloidogenic pathway, that is, initiated by α-secretase within the Aβ domain and precludes Aβ formation.

Despite the ongoing debates about the validity of amyloid cascade hypothesis, targeting amyloidogenic processing of APP is still considered a valid strategy to develop disease-modifying AD therapies (Zhao et al., 2020). New evidence continues to emerge to support the idea that deficiencies in APP trafficking and clearance of Aβ peptides is the initiating event of AD pathogenic processes (Tan and Gleeson, 2019; Zhao et al., 2020). Knowing the importance of protein glycosylation in mediating a plethora of biological functions (Kristí and Lauc, 2017; Akasaka-Manya and Manya, 2020) and considering the fact that most known AD-related molecules are either modified with glycans or play a role in glycan regulation, glycobiology may represent an interesting new insight into the understanding of AD, and a potential for new therapeutic approaches (Haukedal and Freude, 2021). The altered glycan profile of APP in the brain and cerebrospinal fluid (CSF) of AD patients versus healthy controls (Pålsson et al., 1992; Chum et al., 2017; Boix et al., 2020; Moran et al., 2021) has been reported. Particularly, changes in O-glycosylation have been related to differences in APP processing and Aβ generation (Kitazume et al., 2010; Akasaka-Manya et al., 2017; Liu et al., 2017). APP695 is modified by a number of O-glycosylation moieties in several sites, both for mucin-linked O-glycans (O-GalNAc or N-acetylgalactosamine) and O-GlcNAc (N-acetylglucosamine) as observed in Chinese hamster ovary cells (CHO) and human CSF (Perdivara et al., 2009; Halim et al., 2011). O-GlcNAcylation has been shown to influence APP cleavage by increasing the nonamyloidogenic processing by α-secretase and reducing the secretion of Aβ in vitro and in vivo (Jacobsen and Iverfeldt, 2011; Yuzwa and Vocadlo, 2014; Chum et al., 2015, 2017). O-GalNAcylation is more abundant on APP, with extended and/or sialylated O-glycans occupying the region close to the β-secretase cleavage site (M671~D672) of APP (Shi et al., 2021), suggesting its possible role in APP ectodomain shedding and Aβ production (Akasaka-Manya et al., 2017; Nakamura and Kurosaka, 2019). Two O-glycosylation sites, Thr663 and Ser667, located at the N-terminal side of β-secretase cleavage site have been reported to contain α-linked terminal GalNAc structure (Shi et al., 2021). Glycosylation on this region has been found to suppress the APP aggregation kinetics of Aβ40 in the absence and presence of APP (glyco)peptides were explored, respectively. Our results demonstrate a unique role of mucin-type O-glycosylation on APP’s secondary structure, proteolytic cleavage, and aggregation properties and offer an important insight into glycosylation driven changes of the intrinsic properties of APP derived peptides.

### METHODS

#### Materials

Tentagel S RAM resin was obtained from Advanced ChemTech (Louisville, KY). Fmoc-protected amino acids, and coupling reagents, 1-hydroxybenzotriazole (HOBt) and 2-(6-chloro-1H-benzotriazol-1-yl)-1,3,3, tetramethylaminium hexafluorophosphate (HCTU), for peptide synthesis, were purchased from Chem-Impex (Wood Dale, IL). N, N, N'-Diisopropylethylamine (DIPEA) was purchased from Acros Organics (Thermo Fisher Scientific, Waltham, MA). Trifluoroacetic acid (TFA), thiouanisole, and all solvents (DMC, DMF, acetonitrile, and water) were of HPLC grade and purchased from Fisher Scientific (Atlanta, GA) or Sigma-Aldrich (St. Louis, MO). PBS buffer was prepared using sodium phosphate (mono- and dibasic) from Fisher Scientific (Pittsburg, PA). The O-glycosylated GalNAc building blocks of Ser 1 and Thr 2 for glycopeptide synthesis were prepared as published previously by our group (Singh et al., 2020; Beckwith et al., 2021). Recombinant human BACE-1 (rhBACE-1) and BACE-1 fluorogenic peptide substrate IV (MCA-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-Lys(DPN)-Arg-Arg-NH2) were from R&D Systems (catalog #ES004 and #931-AS, respectively).

#### Synthesis of APP (Glyco)peptides

All peptide analogs of APP were synthesized using standard Fmoc chemistry and solid-phase peptide synthesis (SPPS) on a PS3 automated peptide synthesizer (Protein Technologies Inc., Tucson, AZ). The amino acid couplings on the synthesizer were done using a 4-fold excess of amino acids, HOBt, and HCTU, in the presence of 0.4 MN-methylmorpholine (NMM) in DMF. The Fmoc protecting group was removed using 20% piperidine in DMF. For glycopeptides, at the desired site of glycosylation, the Fmoc-protected pentafluorophenyl ester of Ser-O-GalNAc 1 and/or Thr-O-GalNAc 2 was coupled manually using a 1.5-fold excess, in the presence of DIPEA.
(pH 8) for 16 h. After coupling was confirmed using the ninhydrin test, the remainder of the peptide’s amino acid sequence was completed on the PS. All the (glyco)peptides were cleaved from the resin using a TFA/thioanisole/water mixture in 95:2.5:2.5 ratio for 3 h, followed by precipitation in cold methyl-tert-butyl-ether (MTBE) to precipitate the crude (glyco)peptide. For glycopeptides, the acetylated crude was deprotected using 0.01 M NaOH solution for 15 min to remove all the O-acetyl groups on the glycan moiety attached to the peptide sequence. Lastly, the crude was lyophilized to yield the final crude deacetylated glycopeptide or its nonglycosylated counterpart.

**Purification and Characterization of APP (Glyco)peptides**

Purification of all (glyco)peptides and their corresponding analyses were performed on a 1,260 Agilent Infinity system. The analytical RP-HPLC method uses a Phenomenex Aeris Peptide C18 column (150 mm × 4.6 mm, 3.6 μm, 100 Å) at 0.8 ml/min flow rate or a Vydac Denali C18 column (250 mm × 4.6 mm, 5 μm, 120 Å) at 1 ml/min flow rate, with 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B) as the eluents. The elution gradient for analytical RP-HPLC purification was 0–60% B over 30 min. The preparative RP-HPLC method uses the Grace Vydac monomeric C18 column (250 mm × 22 mm, 15–20 μm, 300Å) at 10 ml/min flow rate, with 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B) as the eluents. The elution gradient for preparative RP-HPLC purification was 0–50% over 110 min. The (glyco)peptides were detected at 214 nm by using a UV-Vis detector (Agilent 1,260 Infinity DAD). Purified (glyco)peptides were characterized by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) with a Voyager-DE STR system or a Bruker Microflex system, using α-cyano-4-hydroxycinnamic acid as matrix.

**Conformational Analysis of APP (Glyco)peptides**

All (glyco)peptides were analyzed for their secondary structure using circular dichroism (CD) spectroscopy on a Jasco-810 spectropolarimeter (Jasco, Easton, MD) in three solvent systems: water, 10 mM sodium phosphate buffer (pH 7.4), and 50% trifluoroethanol (TFE) in water (v/v) mixture. The CD spectra were recorded using a quartz cell of 1 mm optical path length over a wavelength range of 180–25 nm with a scanning speed of 100 nm/min and a response time of 4 s at 25°C. A concentration of 0.065 mg/ml, determined using the analytical RP-HPLC method, gave the lowest signal-to-noise ratio for all (glyco)peptides. All spectra were baseline-corrected to account for the signal contribution from solvent and then converted into molar ellipticity (deg cm²dmol⁻¹) (Sreerama and Woody, 2000). Lastly, the percentages of all secondary structures were determined using the BeStSel method (Micsonai et al., 2018; Singh et al., 2021).

**Proteolytic Activity and Analysis of APP (Glyco)peptides With BACE-1**

All APP-based substrates were prepared as 10 mM stocks in DMSO. Before proteolysis, the activity of BACE-1 was verified by the reaction with the fluorogenic BACE-1substrate Mca-SEVNLDAEFRK(Dnp)RR-NH₂ (Koike et al., 1999) as per the manufacturer’s instructions. For the proteolysis assay, APP-based substrates were diluted in BACE-1 activity buffer (0.1 M sodium acetate, pH 4.0) to the final assay concentration of 100 μM. BACE-1 was diluted to 50 nM final concentration. Reactions were incubated for 24 h at 37°C in the dark. After the incubation period, the enzyme cleavage solutions containing APP-based substrates and BACE-1 were analyzed using the analytical RP-HPLC method on the Aeris C18 column with 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B) as eluents and 0–60% B as the elution gradient over 30 min with a flow rate of 0.8 ml/min, and detection at 214 nm or the Vydac Denali C18 column with 0.1% TFA in water (A) and 0.1% TFA in acetonitrile (B) as eluents and 0–60% B as the elution gradient over 30 min with a flow rate of 1 ml/min, and detection at 214 nm. The identity of intact and cleaved (N- and C-terminal) fragments of (glyco)peptides in the absence and presence of BACE-1 (β-secretase) was confirmed by MALDI-TOF and their percentages were evaluated by the integration of the RP-HPLC peaks (averaged from two injections).

**Preparation of Aβ40 Peptide for Aggregation Kinetics Assay With APP (Glyco)peptides**

Aβ40 peptide was synthesized on a PS solid phase peptide synthesizer (Protein Technologies Inc., Woburn, MA) using the standard Fmoc strategy. The resulting crude peptide was purified by reversed-phase high-performance liquid chromatography (RP-HPLC) using a C18 column and characterized by matrix-assisted laser desorption ionization (MALDI) mass spectrometry. The peptide was monomerized as described previously before use (Liu et al., 2018). Lyophilized peptide powder was dissolved in aqueous NaOH solution (2 mM), and the pH was adjusted to ~11 by using 100 mM NaOH solution. The solution was sonicated for 1 h in an ice–water bath and then filtered through a 0.22 μm filter (Millipore) and kept on ice before use. The concentration of the peptide solution was determined by using the tyrosine UV absorbance at 280 nm (ε = 1280 M⁻¹ cm⁻¹).

**Aggregation Kinetics Assay of Aβ40 With APP (Glyco)peptides**

The aggregation kinetics of Aβ40 in the absence and presence of APP (glyco)peptides was performed using ThT binding assay. The monomerized Aβ40 peptide solution was diluted to a final concentration of 10 μM in 50 mM phosphate buffer (pH 7.4) and 20 μM ThT dye. For the co-incubation assays with APP (glyco)peptides, APP stock solutions of 120 μM were added to the prepared Aβ40 for final (glyco) peptide concentrations of
10 µM or 50 µM and Aβ40 concentration of 10 µM in 50 mM phosphate buffer (pH 7.4) with 20 µM ThT dye. 100 µL of each prepared solution was run in triplicate of a 96-well microplate (Costar black, clear bottom). The plate was sealed with a microplate cover and loaded into a Gemini SpectraMax EM fluorescence plate reader (Molecular Devices, Sunnyvale, CA) and incubated at 37°C. The ThT fluorescence was measured from the bottom of the plate at 10 min intervals, with 5 s of shaking, and with an excitation and emission wavelengths of 440 and 480 nm, respectively. Error bars of triplicate samples are shown for the particular data points.

**AFM Analysis of Aβ40 With APP (Glyco)peptides**

AFM was employed to monitor the morphological changes of Aβ40 incubated in the absence and presence of tyrosine glycosylated (14 and 16) and nonglycosylated APP analogues (13 and 15). Aliquots (15 µL) of Aβ40 solutions were collected directly from the aggregation kinetics assay and spotted onto the microplate cover and loaded into a Gemini SpectraMax EM fluorescence plate reader (Molecular Devices, Sunnyvale, CA) and incubated at 37°C. The ThT fluorescence was measured from the bottom of the plate at 10 min intervals, with 5 s of shaking, and with an excitation and emission wavelengths of 440 and 480 nm, respectively. Error bars of triplicate samples are shown for the particular data points.

**RESULTS AND DISCUSSION**

**APP-Based (Glyco)peptide Synthesis and Characterization**

The short APP (glyco) peptide fragments, part of the APP 661–680 region, were prepared. The amino acid sequence included Aβ1-19 DAEFRHDSG at the C-terminal end and either EISEVKM or EISEVNL (NL = Swedish mutation) at the N-terminus to incorporate the β-secretase (BACE-1) cleavage site (M ~ D or L ~ D). Further extension of the backbone with the additional four amino acids (IKTE), furnished a platform for site-specific O-glycosylation of Thr663 and Ser667 residues that may impact APP’s proteolytic processing due to their proximity to the BACE-1 cleavage site (Goth et al., 2018; Nakamura and Kurosaka, 2019). Hence, APP glycopeptides bearing “mucin-type” O-glycosylation, α-N-acetylglactosamine (GalNAc), on Thr663 and/or Ser667 and their nonglycosylated counterparts were prepared using standard Fmoc-based automated solid-phase peptide chemistry (Scheme 1). For glycopeptides, the building block approach was used for the incorporation of O-glycosylated Ser 1 and/or Thr 2 in the sequence. The organic synthesis of the building blocks was achieved using our previously published protocols (Singh et al., 2020; Beckwith et al., 2021). The purity of the Ser/Thr building blocks 1 and 2, respectively, were confirmed by RP-HPLC and MALDI-TOF mass spectrometry. NMR spectra ascertained the α-linkage (Singh et al., 2020; Beckwith et al., 2021).

Automated solid-phase peptide synthesis (SPPS) approach on Tentagel S RAM resin was used to assemble the APP (glyco) peptides. For glycopeptides, the O-glycosylated Ser/Thr building blocks one and two, respectively, were manually coupled at the desired site of glycosylation, Thr663 and/or Ser667, of the growing peptide chain. After completion of the (glyco)peptide sequence, the resin was treated with trifluoroacetic acid (TFA), with water and thioanisole as scavengers. The crude acetylated glycopeptides were further deprotected under basic conditions to remove acetyl groups from the glycan moiety and obtain final deacetylated glycopeptides (4, 6, 8, 9, 11, and 12). The corresponding nonglycosylated peptides (3, 5, 7, and 10) were also prepared as above except for introducing usual Fmoc-Thr(tBu)/Ser(tBu)-OH amino acids, instead of their O-glycosylated analogs (Scheme 1). (Glyco)peptides 3–12 were obtained in high purity, as indicated by their RP-HPLC elution profiles and MALDI-TOF MS analysis (Table 1 and Supplementary Material S2–S11). As expected, the RP-HPLC analysis revealed difference in retention time (t_R) between the Swedish-mutated peptide analogs and their native pairs. The Swedish-mutated (glyco)peptides 5, 6, 10–12 exhibited a 1.5 min (on average) longer t_R compared to their native counterparts 3, 4, 7–9, respectively, due to increased hydrophilicity of the peptide sequence (Table 1) (Mant et al., 1989; Singh et al., 2021). In contrast, the addition of the GalNAc moiety at either Ser667 (4 and 6) or Thr663 (8 and 11) residue resulted in a decrease in the t_R by 0.4 min (on average) compared to their nonglycosylated counterparts 3, 5, 7, and 10, respectively, due to increased hydrophilicity of the glycopeptide sequences (Table 1) (Singh et al., 2021). The attachment of GalNAc moiety at both glycosylation sites (12), further decreased the t_R by 0.5 min compared to its monoglycosylated counterpart 11 (t_R = 18.9 min, Table 1).

**Conformational Properties of APP (Glyco)peptides**

To study the role of O-glycosylation on the conformation of APP glycopeptides, circular dichroism (CD) spectroscopy was used to probe the secondary structure in three different solvents, water, sodium phosphate buffer (10 mM, pH 7.4), and 50% trifluoroethanol (TFE) in water (v/v) (Figure 1). The spectra were further analysed for secondary structure estimations by Beta Structure Selection (BeStSel) method, specifically designed for the analysis of beta sheet-rich proteins (Table 2) (Micsonai et al., 2015, 2018).

In water, the addition of N-terminal fragment, EISEVKM (native) or EISEVNL (Swedish-mutated), to Aβ1-19 in 3 and 5, respectively, exhibited characteristics of β-sheet structure that closely resembled the CD spectra of other Aβ variants in water (J. and G., 1991; Juszczyk et al., 2005; Lambermon et al., 2005). However, further extension of the N-terminal fragment with the additional four amino acids (IKTE) in native 7 and Swedish-mutated 10, respectively, increased the overall hydrophilicity of Aβ1-19 and caused a conformation shift from β-sheet to random coil (Figure 1A). This agrees with our previous work...
where addition of the N-terminal fragment, IKTEEISEVKM (native), to β-sheet-forming Aβ(1–23) peptide in 13, was also largely disordered (Singh et al., 2021). Deconvolution of the spectra revealed that native peptide 3 had the highest amount of β-structure (85.2%, anti-parallel β-sheet, parallel β-sheet, and β-turn), with the majority being anti-parallel β-sheet (59.9%), and the remaining being α-helix (14.8%) (Table 2). The presence of the Swedish double-mutation in 5, resulted in an increase in α-helix and decrease in the β-structure amounts (34.5 and 57.8%, respectively). The distribution of α-helix and β-structure content in 5 is similar to the Swedish-mutated Aβ(1–23) peptide 15, (Juszczyk et al., 2005; Singh et al., 2021). CD spectra clearly indicates that regardless of the Swedish mutation, addition of the N-terminal fragment, IKTEEISEVKM or IKTEEISEVNL, to
Aβ-(1–9) significantly increased the percentage of random coil in 7 and 10 (85.1 and 90.7%, respectively). Site-specific O-glycosylation of Ser667 in glycopeptides 4 and 6 caused their structure to be largely disordered (87.1% and 41.4%, respectively) with complete loss of parallel β-sheets compared to their nonglycosylated counterparts 3 and 5, respectively (Figure 1A). This effect was more pronounced for the native glycopeptide 4 where β-structure along with α-helix was significantly reduced (12.9% and 0%, respectively). On the other hand, the Swedish-mutated glycopeptide 6 was less prone to change in its β-structure and α-helix amounts (39.4% and 19.2%, respectively) (Table 2). Also, the site-specific O-glycosylation of Thr663 in glycopeptides 8 and 11 did not significantly change the secondary conformation compared to their nonglycosylated counterparts 7 and 10, respectively, that were already largely disordered in water (85–90%). Hence, we were able to confirm that the addition of a single GalNAc moiety in APP 661–694 derived glycopeptides is able to break ordered secondary structures and cause it to be disordered in water (Singh et al., 2021). Interestingly, by increasing the glycan valency in glycopeptides 9 and 12, the amount β-structure increased (64.8 and 55.0%, respectively) and random coil decreased (22.4 and 27.0%, respectively). Therefore, glycan valency is an important determinant of the secondary structure of APP glycopeptides.

To evaluate secondary structure in a more physiologically relevant buffer setting, the CD spectra of (glyco)peptides were recorded in sodium phosphate buffer of low ionic strength (10 mM, pH 7.4). As expected, the (glyco)peptides indicated the presence of an unfolded state and were partially disordered with some β-structure properties. Deconvolution of the spectra revealed a prominent presence of random coil (25–77%) and antiparallel β-sheet (17–48%), followed by β-turn (7–34%), and lastly, α-helix (0–10%) (Figure 1B and Table 2) (Hortschansky et al., 2005; Tew et al., 2008; Singh et al., 2021). The Swedish-mutated diglycosylated peptide 12 showed the highest amount of antiparallel β-sheet (47.9%) whereas its monoglycosylated counterpart 11 had the highest amount of random coil (76.8%) in this solvent system. Notable, in the absence of parallel β-sheets, the ratio of the remaining structural elements varied depending on the modifications (Swedish mutation and/or glycosylation) incorporated into the peptide sequences (Figure 1B and Table 2). These findings are in agreement with the previously reported CD data for Aβ peptides of different length; the Aβ-(1–42) peptide exhibited slightly higher α-helix and random coil content compared to Aβ-(1–16) peptide that has higher β-sheet and β-turn content (Tew et al., 2008). Likewise, our previously reported (glyco)peptides containing longer Aβ-(1–23) fragment (13–16) showed higher α-helix and random coil, and lower antiparallel β-sheet content, in sodium phosphate buffer (Singh et al., 2021) compared to (glyco)peptides analysed in this study that contain shorter Aβ-(1–9) fragment (3–12). Hence, Aβ occurs in various isoforms that differ by the number of residues at the C-terminal end of the peptides, which impacts the secondary structural preferences of the peptides in solution.

APP is an integral membrane protein whose behaviour can be modified by molecules such as trifluoroethanol (TFE) that partition the membrane-water interface and change the physiochemical properties of the lipid bilayer (Barry and Gawrisch, 1994; Özdirekcan et al., 2008). We have previously investigated the effects of TFE on a molecular level using CD spectroscopy to obtain an account of the α-helix-forming potential of model (glyco)peptides 13–16 containing the
Ty#{681} O-linked glycosylation in Aβ-(1–23) region of APP (Singh et al., 2021). Upon addition of TFE into water (1:1, v/v), the (glyco)peptides showed a significant increase in α-helix and random coil content and decrease in β-structure content (Figure 1C). Upon further analysis, shorter native peptide 3 had slightly higher α-helix content (66.2%) than its Swedish-mutated counterpart 5 (59.9%), however, this difference was larger between the longer native peptide 7 (88.7%) and its Swedish-mutated counterpart 10 (36.8%) (Table 2). Regardless of the length of Aβ fragment, the Swedish mutation significantly reduced the amount of α-helix and increased β-sheet and random coil secondary structure elements in this solvent system. Similarly, site-specific O-glycosylation of Thr#{663} and Tyr#{681} (Singh et al., 2021) slightly decreased the α-helix and increased the random coil content in native glycopeptides, 8 and 14 respectively, whereas it increased α-helix and decreased random coil content in Swedish-mutated glycopeptides, 11 and 16 respectively, with this effect being more pronounced for 16. Lastly, regardless of the Swedish mutation, the attachment of two GaINAc moieties on Thr#{663} and Ser#{667} within the peptide sequence drastically increased the α-helix content in 9 and 12 (94.4% and 86.2%, respectively), in this solvent system. These findings suggest that in membrane-mimicking conditions, excess O-glycosylation can hamper the effects of the Swedish mutation on secondary structure and prompt it to become largely α-helical.

**BACE-1 Activity of APP (Glyco)peptides**

Glycosylation can alter substrate recognition and impact enzyme activity in either a positive (enhancing) or negative (inhibiting) manner (Goettig, 2016; Goth et al., 2018). The mucin-type O-linked glycosylation of a protein may not only affect its conformation but also affect its transport and localization in the cell (Matsuura et al., 1989; Chen et al., 2002). Proteases are highly regulated by post-translational modifications and drive fate, localization, and activity of many proteins (Bond, 2019). Certain mutations can also affect the subcellular localization of the cleavage event by crucial proteases and mediate a different cellular mechanism for the protein (Haass et al., 1995). We have previously reported that the Swedish mutation is an important criterion for enhancing both ADAM10 (α-secretase) and BACE1 (β-secretase) cleavage rates of Aβ-(1–23) model (glyco)peptides.

**TABLE 2** Summary of the secondary content (%) present in APP (glyco)peptides 3–12 determined by BeStSel for CD spectra obtained in (A) water (B) 10 mM sodium phosphate buffer, pH 7.4, and (C) TFE/water = 1:1 (v/v)▫.

| APP (glyco)peptides | α-H (%) | β-AP (%) | β-P (%) | β-T (%) | RC (%) |
|---------------------|---------|----------|---------|---------|--------|
| (A)                 |         |          |         |         |        |
| APP#{665-680} (3)   | 14.8    | 59.9     | 18.1    | 7.2     | 0.0    |
| APP#{665-680}S* (4) | 0.0     | 0.0      | 0.0     | 12.9    | 87.1   |
| APP#{665-680}NL (5) | 34.5    | 21.9     | 35.9    | 0.0     | 7.7    |
| APP#{665-680}NL-S* (6) | 19.2    | 30.8     | 0.0     | 8.6     | 41.4   |
| APP#{661-680} (7)   | 0.0     | 8.3      | 0.0     | 6.6     | 85.1   |
| APP#{661-680}T* (8) | 1.4     | 5.4      | 0.0     | 5.7     | 87.4   |
| APP#{661-680}T*, S* (9) | 12.8    | 48.2     | 0.0     | 16.6    | 22.4   |
| APP#{661-680}NL (10) | 0.0    | 9.3      | 0.0     | 0.0     | 90.7   |
| APP#{661-680}NL-T* (11) | 0.0    | 0.0      | 0.0     | 12.5    | 87.5   |
| APP#{661-680}NL-T*, S* (12) | 18.0    | 45.8     | 0.0     | 9.2     | 27.0   |
| (B)                 |         |          |         |         |        |
| APP#{665-680} (3)   | 6.1     | 39.8     | 0.0     | 19.8    | 34.3   |
| APP#{665-680}S* (4) | 9.3     | 33.6     | 0.0     | 14.9    | 42.2   |
| APP#{665-680}NL (5) | 6.7     | 34.6     | 0.0     | 23.2    | 35.6   |
| APP#{665-680}NL-S* (6) | 0.0    | 41.3     | 0.0     | 33.5    | 25.3   |
| APP#{661-680} (7)   | 8.4     | 38.1     | 0.0     | 15.7    | 39.8   |
| APP#{661-680}T* (8) | 8.8     | 42.6     | 0.0     | 18.3    | 30.4   |
| APP#{661-680}T*, S* (9) | 9.5    | 24.6     | 0.0     | 17.1    | 48.7   |
| APP#{661-680}NL (10) | 0.0    | 34.4     | 0.0     | 15.0    | 50.6   |
| APP#{661-680}NL-T* (11) | 0.0   | 16.6     | 0.0     | 6.6     | 76.8   |
| APP#{661-680}NL-T*, S* (12) | 3.6   | 47.9     | 0.0     | 17.2    | 31.2   |
| (C)                 |         |          |         |         |        |
| APP#{665-680} (3)   | 66.2    | 2.7      | 12.6    | 0.9     | 17.6   |
| APP#{665-680}S* (4) | 52.2    | 0.0      | 0.0     | 2.9     | 44.9   |
| APP#{665-680}NL (5) | 59.9    | 3.5      | 3.2     | 0.0     | 33.3   |
| APP#{665-680}NL-S* (6) | 66.7    | 0.0      | 0.7     | 0.0     | 32.6   |
| APP#{661-680} (7)   | 88.7    | 0.0      | 0.0     | 3.2     | 8.1    |
| APP#{661-680}T* (8) | 85.7    | 0.0      | 0.0     | 6.0     | 8.3    |
| APP#{661-680}T*, S* (9) | 94.4    | 0.0      | 0.0     | 5.6     | 0.0    |
| APP#{661-680}NL (10) | 36.8    | 9.7      | 7.5     | 0.0     | 46.0   |
| APP#{661-680}NL-T* (11) | 40.3    | 6.1      | 4.7     | 0.0     | 48.9   |
| APP#{661-680}NL-T*, S* (12) | 86.2    | 0.0      | 3.1     | 6.5     | 4.3    |

*The content is divided into α-helix (α-H), anti-parallel β-sheet (β-AP), parallel β-sheet (β-P), β-turn (β-T), and random coil (RC).
TABLE 3 | Proteolytic cleavage of APP (glyco)peptides 3–12 upon treatment with BACE-1 enzyme (K\text{M}-D/NL-D cleavage site)\(^\text{a}\).

| APP (glyco)peptides | BACE-1 activity |
|---------------------|----------------|
| Recovered (%)       | Cleaved (%)    |
| APP\(_{665-690}\)   | 96.5           | 4.48          |
| APP\(_{665-690}\)-S\(_\ast\) | 98.6           | 1.40          |
| APP\(_{665-690}\)\(_\ast\)-N\(_\ast\) | 95.9           | 1.40          |
| APP\(_{665-690}\)-T\(_\ast\), S\(_\ast\) | 95.9           | 4.20          |
| APP\(_{665-690}\)\(_\ast\)-N\(_\ast\) | 20.3           | 79.7          |
| APP\(_{665-690}\)\(_\ast\)-T\(_\ast\), S\(_\ast\) | 1.90           | 98.1          |
| APP\(_{665-690}\)\(_\ast\)-N\(_\ast\)-N\(_\ast\) | 3.90           | 96.1          |
| APP\(_{665-690}\)-T\(_\ast\) | 100\(^\text{b}\) | 0.0\(^\text{b}\) |
| APP\(_{665-690}\)-T\(_\ast\)+\(_\ast\) | 100\(^\text{b}\) | 0.0\(^\text{b}\) |
| APP\(_{665-690}\)\(_\ast\)-N\(_\ast\) | 88.6\(^\text{b}\) | 13.1\(^\text{b}\) |
| APP\(_{665-690}\)\(_\ast\)-N\(_\ast\)-T\(_\ast\) | 57.4\(^\text{b}\) | 42.4\(^\text{b}\) |

\(^{\text{a}}\)The values were calculated as described in the Methods with SD <5% and identity of the fragments was determined by RP-HPLC, analysis and confirmed by MALDI-TOF (see the Supplementary Material S20–S32).

\(^{\text{b}}\)Reported in Singh et al., 2021.

Other key aspects affecting BACE-1 cleavage rates in the presence of the Swedish mutation were the length of the C-terminal Aβ fragment and the glycan position relative to the cleavage site. For example, 16 contains Aβ-(1–23) C-terminal fragment and is cleaved to a much lesser extent (42.4%) by BACE-1 than 11 that contains Aβ-(1–9) C-terminal fragment (98.1%). Moreover, the relative position of the GalNAc moiety on Thr\(_{663}\) and Tyr\(_{681}\) in 11 and 16, respectively, can also influence enzymatic activity. Even though 16 is cleaved to a lesser extent than 11 by BACE-1, the ~3-fold increase in cleaved products compared to its non-glycosylated counterpart 15 is observed. This further points to a stronger effect of Tyr\(_{681}\) O-glycosylation on the C-terminal Aβ fragment in accelerating BACE-1 activity. Therefore, we can postulate that in the presence of the Swedish mutation, excess O-glycosylation proximal to BACE-1 cleavage site can significantly increase the cleavage propensity of the peptides for the amyloid pathway, with this effect being more pronounced when the glycosylation is on the C-terminal Aβ side of the cleavage site.

The subcellular localization of BACE-1 cleavage of Swedish-mutated APP differs greatly from that for native APP, where the former is localized to a post Golgi compartment for Aβ generation and outcompetes anti-amyloidogenic processing by α-secretases (Haass et al., 1995; Thinkaran et al., 1996). However, little is known regarding the regulatory role of mucin-type O-linked glycosylation of APP on BACE-1 activity, and these results are particularly interesting, since Aβ peptides in CSF of AD patients are heavily glycosylated by mucin-type O-linked glycans (Halim et al., 2011). Thus, we can speculate that both Swedish mutation and mucin-type O-linked glycosylation increase APP processing because the former provides a better cleavage site for BACE-1, and the latter changes the conformation and increases the sensitivity of the protein to BACE-1.

Aggregation Kinetics of APP (Glyco)peptides on Aβ\(_{40}\) Fibrillogenesis

We adopted the widely used thioflavin T (ThT) assay (Xue et al., 2017) to investigate how O-glycosylation impacts the kinetics of fiber formation of Aβ\(_{40}\), a model peptide for studying the dynamics of protein aggregation. The aggregation kinetic profile of Aβ\(_{40}\) peptide (10 µM) exhibited a typical sigmoidal curve with three different regions: a lag phase associated with nucleation, a rapid growth phase for elongation and polymerization by fibrils, and a final saturation phase dominated with mature fibrils (Figure 2, Supplementary Material S33–S40). At the conditions used in this study, it has been shown that Aβ amyloidogenesis proceeds by a nucleation-dependent polymerization mechanism that involves key soluble oligomeric intermediates (Du et al., 2011; Elbassal et al., 2017). The half time (\(t_{50}\)) of the growth phase of the Aβ\(_{40}\) amyloidogenesis was approximately 8 h (Figure 2, Supplementary Material S33–S40), where \(t_{50}\) is defined as the time at which the fluorescence intensity reaches the midpoint between the pre- and post-aggregation baselines.
FIGURE 2 | Effect of APP peptides 3, 5, 7, 10, 13, and 15 (A) and glycopeptides 4, 6, 8, 9, 11, 12, 14, 16 (B) on the aggregation kinetics of Aβ40 (10 µM) using ThT fluorescence assay in phosphate buffer (50 mM, pH 7.4) at 37°C. The concentration of (glyco)peptides was 10 and 50 µM. *Peptide 13 was run at 10 and 25 µM. Aggregation half-time (Δt$_{50}$) = APP (glyco)peptide t$_{50}$ – Aβ40 t$_{50}$. The t$_{50}$ values are means of triplicate kinetics results. Alongside are tapping mode atomic force microscopy images of Aβ40 fibril growth upon 24 h incubation with nonglycosylated peptides, 13 and 15 (A) and Tyr-O-glycopeptides, 14 and 16 (B).
Although recent studies have implicated small soluble oligomers, as the main culprits of Aβ toxicity and AD pathogenesis (Yang et al., 2017), very little is known about the exact mechanism of oligomeric assembly and the conformation of peptides in this early event of Aβ aggregation. In the presence of APP (glyco)peptides 3–16 at two concentrations (10 and 50 µM), the kinetics of aggregation of Aβ40 was described by a sigmoidal curve, with a lag phase that varied depending on the internal modifications of the (glyco)peptides such as the Swedish mutation, site-specific O-glycosylation, glycan valency and/or sequence length. The curves reached a plateau after approximately 24 h (Supplementary Material S33–S40). The nonglycosylated peptides 3, 5, and 7 displayed no marked effect either on the lag phase (Δt₅₀ < 2 h, Figure 2A) or the final ThT fluorescence intensity in comparison to control Aβ40 peptide alone (Supplementary Figures S1A–S3A, Supplementary Material S33–S35). Interestingly, we observed a slight delay in the aggregation process by the Swedish-mutated peptide 10 (Δt₅₀ = 3.2 h at 50 µM, Figure 2A, Supplementary Figure S4A, Supplementary Material S36) with extended N-terminal domain. Increasing the C-terminal domain sequence in 13 and 15, to include Aβ-(1–23) fragment, led to a much larger effect on the lag phase (Supplementary Figures S5A, S6A, Supplementary Material S38–S39), with Δt₅₀ = 7.1 h for 13 (25 µM) and Δt₅₀ = 5.2 h for 15 (50 µM) (Figure 2A), indicating an inhibitory effect on Aβ40 aggregation. Notably, we observed a complete saturation of the ThT signal for native peptide 13 at higher concentration (50 µM) (Supplementary Figures S5A,B, Supplementary Material S38). Hence, the aggregation of Aβ40 in the presence of nonglycosylated peptides 3, 5, 7, 10, 13, or 15 displayed a longer lag phase when the length of the Aβ fragment was increased. The effect of the Swedish mutation was less clear and varied regardless of peptide length.

To evaluate Aβ40 aggregation in the presence of glycopeptides, we first performed kinetics with the free GalNAc sugar (10 and 50 µM) that showed minimal difference in Δt₅₀ values (Δt₅₀ <0.5 h, Figure 2B). The presence of a single GalNAc moiety on Ser⁶⁶⁷ in native glycopeptide four increased the lag phase substantially (Δt₅₀ = 6.7 h at 50 µM, Figure 2B, and Supplementary Figure S1B in the Supplementary Material S33) and delayed Aβ40 aggregation much more compared to its non-glycosylated counterpart 3. Extension of the N-terminal domain sequence in native glycopeptide eight by IKTE, slightly decreased the Δt₅₀ value (Δt₅₀ = 5 h at 50 µM, Figure 2B, and Supplementary Figure S3B in the Supplementary Material S35) compared to four. However, increasing the glycan valency in nine resulted in gain in inhibition of Aβ40 aggregation and further increase of the lag phase (Δt₅₀ = 7.7 h at 50 µM, Figure 2B, Supplementary Figure S3C, Supplementary Material S36). Regardless of the length of the N-terminal domain sequence, the presence of the Swedish mutation in 6 and 11 completely suppressed the inhibitory effect of O-glycosylation on Aβ40 aggregation exhibited by 8 (Δt₅₀ = 0 h at 50 µM, Figure 2B, and Supplementary Figure S2B, S4B in the Supplementary Material S34,S37). A drastic increase in the Δt₅₀ value for diglycosylated and Swedish mutated peptide 12 (Δt₅₀ = 7.8 h at 50 µM, Figure 2B, and Supplementary Figure S4C in the Supplementary Material S37) clearly indicated that O-glycosylation at multiple sites of attachment can overcome the effect of the Swedish mutation and cause Aβ40 to aggregate at slower rates. Consistent with their nonglycosylated versions 13 and 15, the extension of the Aβ fragment and site-specific O-glycosylation of Tyr⁶⁸¹ in 14 and 16 showed the largest difference in lag phase and strongest inhibition of Aβ40 aggregation profile, with Δt₅₀ = 12.1 h for 14 (50 µM) and Δt₅₀ = 15.2 h for 16 (50 µM) (Figure 2B, and Supplementary Figures S5C, S6B in the Supplementary Material S39–S40). Along with having a prolonged lag phase, 14 also reduces the final ThT fluorescence intensity dramatically (~50%), suggesting a significant interference in Aβ40 aggregation. Therefore, our results suggest that O-glycosylation inhibits Aβ40 aggregation in a concentration-dependent manner, and this effect is more pronounced when the glycopeptides contain the longer Aβ-(1–23) fragment and GalNAc modification on Tyr⁶⁸¹(14 and 16). It is also important to mention that by reducing the length of the Aβ fragment to Aβ-(1–9), we were able to detect the key differences between the Swedish-mutated (6 and 11) and mono-/diglycosylated analogues (4, 8, 9, and 12) on Aβ40 aggregation kinetics.

The morphology of the tyrosine (glyco) peptide aggregates (13–16) co-incubated with Aβ40 was examined using atomic force microscopy (AFM). In the absence of (glyco)peptides, Aβ40 forms a dense meshwork of amyloid fibrils (Figure 2). In the presence of native peptide 13 (25 µM) lower density of Aβ40 fibrils is observed (Figure 2A). Similarly, addition of glycosylated counterpart 14 (50 µM), resulted in less fibrils formed, and the ones formed were shorter in size (Figure 2B). This is consistent with the ThT kinetics data for 13 and 14 at 25 and 50 µM, respectively. The addition of the Swedish-mutated peptide 15 (50 µM) to Aβ40 resulted in the fibrilar morphology similar to that of Aβ40 alone (Figure 2A). However, its glycosylated counterpart 16 was able to partially inhibit the fibril formation, resulting in thinly dispersed and less dense Aβ40 fibril (Figure 2B). Thus, as observed in ThT kinetics, the aggregation of Aβ40 can be delayed by 15 and 16 (50 µM), however, the inhibitory potency is not enough to prevent fibril formation under the current conditions.

Our work parallels and directly complements the study by Liu et al., 2021 that shows Aβ42 peptides bearing Tyr⁶⁸¹ O-glycosylation significantly affect both the aggregation and degradation of Aβ42. Furthermore, similar inhibiting activity of Aβ40 and Aβ42 fibrillogenesis by glycation (Emendato et al., 2018; Milordini et al., 2020) and addition of polysaccharides, such as chitosan (Liu et al., 2015; Hao et al., 2017) and heparin sulfate (Wang et al., 2021) was reported.

CONCLUSION

In summary, the dynamical interplay between O-glycosylation and aggregation affected the structure of peptides and slowed down the aggregation process. The presence of the Swedish mutation led to an increased amount of β-structure in
physiological conditions, with the β-secretase activity being drastically increased, and the aggregation process remaining largely unaffected. However, this effect of the Swedish mutation on the (glyco)peptides was overcome by increasing the number of glycosylation sites near the β-secretase cleavage site, increasing the C-terminal domain (Aβ) sequence relative to the β-secretase cleavage site, and/or having Tyr⁶⁸¹ glycosylated in the Aβ domain, resulting in glycosylation strongly inhibiting the aggregation process of Aβ40. Therefore, our studies demonstrate that O-glycosylation typically supports the non-amyloidogenic processing of APP, however, in FAD cases, it can incline towards the amyloidogenic processing of APP, where its fate lies upon the abundance and position of O-glycans relative to the β-secretase cleavage site.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

YS and MC wrote the manuscript. YS, DO, and RA conducted the synthesis of the glycosylated Thr/Ser building blocks. Synthesis of glycopeptides was done by YS, NV, GM and DO. The CD analysis was done by YS and NV. Proteolytic cleavage assay was done by DM and samples analyzed by YS, GM, and NV. Aggregation kinetics assays and AFM images acquired and analyzed by DR and DD. The senior authorship is shared by DM, DD, and MC.

FUNDING

This research was supported by the National Institute of Health (NIH) Grants R15CA242351 to MC, R15CA249788 to DM, and R15GM116006 to DD, the Alzheimer’s Association AARG-17-531423 to DD, and Palm Health Foundation and Stiles-Nicholson Brain Institute to MC.

ACKNOWLEDGMENTS

The authors are thankful to Dr. Vivian Merk (FAU) and her lab for their atomic force microscopy system that was used in this study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2022.859822/full#supplementary-material

REFERENCES

Akasaka-Manya, K., Kawamura, M., Tsumoto, H., Saito, Y., Tachida, Y., Kitazume, S., et al. (2017). Excess APPO-Glycosylation by GalNAC-T6 Decreases Aβ Production. J. Biochem. 161, 99–111. doi:10.1093/jb/mvw056

Akasaka-Manya, K., and Manya, H. (2020). The Role of APP O-Glycosylation in Alzheimer’s Disease. Biomolecules 10, 1569. doi:10.3390/biom10111569

Alzheimer’s Association (2020). 2020 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 16, 391–460. doi:10.1016/j.jalz.2012.04.008

Barry, J. A., and Gawrisch, K. (1994). Direct NMR Evidence for Ethanol Binding to the Lipid-Water Interface of Phospholipid Bilayers. Biochemistry 33, 8082–8088. doi:10.1021/bi04019a013

Beckwith, D. M., FitzGerald, F. G., Rodriguez Benavente, M. C., Mercer, E. R., Ludwing, A.-K., Michalak, M., et al. (2021). Calorimetric Analysis of the Interplay between Synthetic Tn Antigen-Presenting MUC1 Glycopeptides and Human Macrophage Galactose-type Lectin. Biochemistry 60, 547–558. doi:10.1021/acs.biochem.0c00942

Boix, C. P., Lopez-Font, I., Cuchillo-Ibañez, I., and Sáez-Valero, J. (2020). Amyloid Precursor Protein Glycosylation Is Altered in the Brain of Patients with Alzheimer’s Disease. Alz. Res. Ther. 12, 96. doi:10.1186/s13195-020-00664-9

Bond, J. S. (2019). Proteases: History, Discovery, and Roles in Health and Disease. J. Biol. Chem. 294, 1643–1651. doi:10.1074/jbc.T118.004156

Chen, P.-Y., Lin, C.-C., Chang, Y.-T., Lin, S.-C., and Chan, S. I. (2002). One O-Linked Sugar Can Affect the Coil-To-β Structural Transition of the Prion Peptide. Proc. Natl. Acad. Sci. U.S.A. 99, 12633–12638. doi:10.1073/pnas.192317799

Chun, Y. S., Kwon, O.-H., and Chung, S. (2017). O-GlcNAcylation of Amyloid-β Precursor Protein at Threonine 576 Residue Regulates Traf3ki in Cells and Tissues. Biochemistry 56, 4867–4876. doi:10.1021/acs.biochem.7b03991

Chun, Y. S., Kwon, O.-H., Kim, T.-W., McIntire, L. B., Park, M. K., et al. (2015). Threonine 576 Residue of Amyloid-β Precursor Protein Regulates its Trafficking and Processing. Biochem. Biophys. Res. Commun. 467, 955–960. doi:10.1016/j.bbrc.2015.10.037

Du, D., Murray, A. N., Cohen, E., Kim, H.-E., Simkovsky, R., Dillin, A., et al. (2011). A Kinetic Aggregation Assay Allowing Selective and Sensitive Amyloid-β Quantification in Cells and Tissues. Biochemistry 50, 1607–1617. doi:10.1021/bi1013744

Elbassal, E. A., Morris, C., Kent, T. W., Lantz, R., Ojha, B., Wojcikiewicz, E. P., et al. (2017). Gold Nanoparticles as a Probe for Amyloid-β Oligomer and Amyloid Formation. J. Phys. Chem. C 121, 20007–20015. doi:10.1021/acs.jpcc.7b05169

Emendato, A., Milordini, G., Zacco, E., Sicorello, A., Dal Piaz, F., Guerrini, R., et al. (2018). Glycation Affects Fibril Formation of Aβ Peptides. J. Biol. Chem. 293, 13100–13111. doi:10.1074/jbc.RA118.002275

Goettig, P. (2016). Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Jms 17, 1969–1993. doi:10.3390/jms17121969

Goth, C. K., Vakhruhev, S. Y., Joshi, H. J., Clausen, H., and Schjoldager, K. T. (2018). Fine-tuning Limited Proteolysis: A Major Role for Regulated Site-specific O-Glycosylation. Trends Biochem. Sci. 43, 269–284. doi:10.1016/j.tibs.2018.02.005

Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., et al. (1995). The Swedish Mutation Causes Early-Onset Alzheimer’s Disease by β-secretase Cleavage within the Secretory Pathway. Nat. Med. 1, 1291–1296. doi:10.1038/nm1295-1291

Halim, A., Brinkmalm, G., Rüetschi, U., Westman-Brinkmalm, A., Portelius, E., Zetterberg, H., et al. (2011). Site-specific Characterization of Threonine, Serine, and Tyrosine Glycosylations of Amyloid Precursor Protein/amyloid β-peptides in Human Cerebrospinal Fluid. Proc. Natl. Acad. Sci. U.S.A. 108, 11848–11853. doi:10.1073/pnas.1102664108

Emendato, A., Milordini, G., Zacco, E., Sicorello, A., Dal Piaz, F., Guerrini, R., et al. (2018). Glycation Affects Fibril Formation of Aβ Peptides. J. Biol. Chem. 293, 13100–13111. doi:10.1074/jbc.RA118.002275

Goettig, P. (2016). Effects of Glycosylation on the Enzymatic Activity and Mechanisms of Proteases. Jms 17, 1969–1993. doi:10.3390/jms17121969

Goth, C. K., Vakhruhev, S. Y., Joshi, H. J., Clausen, H., and Schjoldager, K. T. (2018). Fine-tuning Limited Proteolysis: A Major Role for Regulated Site-specific O-Glycosylation. Trends Biochem. Sci. 43, 269–284. doi:10.1016/j.tibs.2018.02.005

Haass, C., Lemere, C. A., Capell, A., Citron, M., Seubert, P., Schenk, D., et al. (1995). The Swedish Mutation Causes Early-Onset Alzheimer’s Disease by β-secretase Cleavage within the Secretory Pathway. Nat. Med. 1, 1291–1296. doi:10.1038/nm1295-1291

Halim, A., Brinkmalm, G., Rüetschi, U., Westman-Brinkmalm, A., Portelius, E., Zetterberg, H., et al. (2011). Site-specific Characterization of Threonine, Serine, and Tyrosine Glycosylations of Amyloid Precursor Protein/amyloid β-peptides in Human Cerebrospinal Fluid. Proc. Natl. Acad. Sci. U.S.A. 108, 11848–11853. doi:10.1073/pnas.1102664108
Yuzwa, S. A., and Vocadlo, D. J. (2014). O-GlcNAc and Neurodegeneration: Biochemical Mechanisms and Potential Roles in Alzheimer’s Disease and beyond. Chem. Soc. Rev. 43, 6839–6858. doi:10.1039/C4CS00038B
Zhao, J., Liu, X., Xia, W., Zhang, Y., and Wang, C. (2020). Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease. Front. Mol. Neurosci. 13, 137. doi:10.3389/fnmol.2020.00137

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Singh, Regmi, Ormaza, Ayyalasomayajula, Vela, Mundim, Du, Minond and Cudic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.